950210 — Prestige Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00
- KR₩481bn
- KR₩408bn
- $0.12m
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -1.27 | -12.5 | -6.51 | -176 | -2.16 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | -2.4 | 3.81 | -10.5 | 149 | -43.2 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 6.49 | -2.64 | 1.94 | -14.4 | -9.07 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 3.33 | -10.4 | -13.6 | -38.2 | -45.6 |
Capital Expenditures | -31.2 | -15.7 | -15.9 | -56.7 | -49.6 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -1.98 | 0.581 | -2.47 | -97.1 | -62.8 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -33.2 | -15.1 | -18.4 | -154 | -112 |
Financing Cash Flow Items | — | — | -11.8 | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 35 | 55.3 | 400 | -3.75 | 40.2 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 5.17 | 29.8 | 368 | -198 | -113 |